Ovid Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Ovid Therapeutics

10/11/2021 22:04

* Ovid Therapeutics Inc  OVID.OQ  reported a quarterly adjusted
loss of 17 cents​​ per share for the quarter ended in September.
The mean expectation of five analysts for the quarter was for a
loss of 18 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* Ovid Therapeutics Inc's reported EPS for the quarter was a
loss of 17 cents​.
* The mean earnings estimate of analysts had fallen by
about 12.9% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Ovid Therapeutics Inc shares had risen by 7.4% this
quarter and gained 56.3% so far this year.
* The company reported a quarterly loss of $11.38 million.
* Wall Street's median 12-month price target for Ovid
Therapeutics Inc is $4.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
This summary was machine generated November 10 at 10:04 p.m.
 ​All figures in US dollars unless otherwise stated